Clinical Research Directory

Inclusion Criteria: * Able to read, understand, and sign an informed consent form before any study procedures. * Male or female adults aged 18 to 75 years with a physician diagnosis of moderate to severe asthma for at least 12 months. * Receiving stable treatment with an inhaled corticosteroid (ICS) plus a long-acting beta₂-agonist (LABA) for at least 2 months before screening. * Pre-bronchodilator FEV₁ between 50% and 80% of predicted normal at screening and baseline. * Demonstrated bronchodilator reversibility, defined as ≥12% and ≥200 mL improvement in FEV₁ (or ≥20% increase in peak expiratory flow) after short-acting bronchodilator use. * ACQ-5 score ≥1.25 and ≤3.0 at screening and baseline. * History of at least one asthma exacerbation in the past 12 months requiring systemic corticosteroids or hospitalization/emergency care. Exclusion Criteria: * Had a moderate or severe asthma exacerbation within 4 weeks before screening. * Have a history of life-threatening asthma, including intubation or respiratory arrest. * Have any other significant pulmonary disease (e.g., COPD, bronchiectasis, pulmonary fibrosis, cystic fibrosis, tuberculosis, lung cancer, or eosinophilic syndromes). * Had bronchial thermoplasty within 2 years before screening. * Used biologic therapies for asthma (e.g., benralizumab, mepolizumab, reslizumab, omalizumab, dupilumab, or tezepelumab) within 6 months or 5 half-lives prior to baseline. * Require immunosuppressive medications or frequent systemic corticosteroids (more than 3 courses in the past 6 months). * Are current smokers or former smokers with \>10 pack-year history or who quit within 6 months before screening. * Have uncontrolled hypertension (systolic ≥160 mmHg or diastolic \>95 mmHg). * Have significant hepatic impairment or any other condition that, in the investigator's opinion, would interfere with study participation or interpretation of results.